Form 4: IN8BIO Executive Receives Stock Option Award
SEC Form 4 Filing
Lawrence Lamb, EVP and CSO of IN8BIO, Inc., was granted a stock option for 250,000 shares as a retention award.
Summary
- Lawrence Lamb, the EVP and CSO of IN8BIO, Inc., received a stock option to purchase 250,000 shares of common stock on September 4, 2024.
- The option's exercise price is $0.47 per share.
- The options vest in installments: 25% on March 4, 2025, 25% on September 4, 2025, and 50% on March 4, 2026, contingent upon continued service.
- The option expires on September 4, 2034.
Sentiment
Score: 7
Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is moderately positive as it reflects ongoing commitment from a key executive.
Positives
- The stock option serves as a retention award for a key executive, Lawrence Lamb.
- The vesting schedule incentivizes continued service and commitment to the company.
Future Outlook
The vesting schedule is contingent upon the Reporting Person continuing to provide service through each vesting date.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders and incentivize long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies like IN8BIO.
- Companies such as Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) have used similar stock option plans to incentivize key personnel.
- The vesting schedule and exercise price are typical for retention awards in this sector.
Stakeholder Impact
- Shareholders may view the stock option as a positive incentive for the executive to drive company performance.
- Employees may see this as a sign of the company's commitment to retaining key talent.
Key Dates
| Date | Description |
|---|---|
| 09/04/2024 | Date of the stock option grant. |
| 03/04/2025 | First vesting date (25% of shares). |
| 09/04/2025 | Second vesting date (25% of shares). |
| 03/04/2026 | Final vesting date (50% of shares). |
| 09/04/2034 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.